Pleiotropic properties of statins via angiogenesis modulation in cardiovascular disease

Fatemeh Zahedipour; Alexandra E. Butler; Ali H. Eid; Amirhossein Sahebkar

doi:10.1016/j.drudis.2022.07.010

Pleiotropic properties of statins via angiogenesis modulation in cardiovascular disease

Fatemeh Zahedipour, Alexandra E. Butler, Ali H. Eid, Amirhossein Sahebkar

UWA Medical School

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Inhibition of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase by statins is affected by inhibiting the active site of the enzyme in a competitive manner. Statins reduce plasma cholesterol by inhibiting its de novo synthesis. In addition, statins impart ‘pleiotropic’ activities that do not directly relate to their ability to decrease cholesterol. The proangiogenic and antiangiogenic characteristics of statins are among these pleiotropic effects. These angiogenic-modifying properties could offer new therapeutic applications. Statins stimulate or suppress angiogenesis in a biphasic manner. Whereas low doses of statin stimulate angiogenesis, high doses reduce protein prenylation and limit cell development and angiogenesis. In this review, we discuss how statins impact angiogenesis, with a particular focus on angiogenesis in stroke and cardiovascular disease (CVD).

Original language	English
Article number	103325
Journal	Drug Discovery Today
Volume	27
Issue number	10
DOIs	https://doi.org/10.1016/j.drudis.2022.07.010
Publication status	Published - Oct 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.drudis.2022.07.010

Cite this

@article{7c9d725f2c264fc7a66f96473e91018d,

title = "Pleiotropic properties of statins via angiogenesis modulation in cardiovascular disease",

abstract = "Inhibition of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase by statins is affected by inhibiting the active site of the enzyme in a competitive manner. Statins reduce plasma cholesterol by inhibiting its de novo synthesis. In addition, statins impart {\textquoteleft}pleiotropic{\textquoteright} activities that do not directly relate to their ability to decrease cholesterol. The proangiogenic and antiangiogenic characteristics of statins are among these pleiotropic effects. These angiogenic-modifying properties could offer new therapeutic applications. Statins stimulate or suppress angiogenesis in a biphasic manner. Whereas low doses of statin stimulate angiogenesis, high doses reduce protein prenylation and limit cell development and angiogenesis. In this review, we discuss how statins impact angiogenesis, with a particular focus on angiogenesis in stroke and cardiovascular disease (CVD).",

keywords = "Angiogenesis, Cardiovascular, Ischemic heart disease, Statins, Vascularization",

author = "Fatemeh Zahedipour and Butler, {Alexandra E.} and Eid, {Ali H.} and Amirhossein Sahebkar",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = oct,

doi = "10.1016/j.drudis.2022.07.010",

language = "English",

volume = "27",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - Pleiotropic properties of statins via angiogenesis modulation in cardiovascular disease

AU - Zahedipour, Fatemeh

AU - Butler, Alexandra E.

AU - Eid, Ali H.

AU - Sahebkar, Amirhossein

PY - 2022/10

Y1 - 2022/10

N2 - Inhibition of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase by statins is affected by inhibiting the active site of the enzyme in a competitive manner. Statins reduce plasma cholesterol by inhibiting its de novo synthesis. In addition, statins impart ‘pleiotropic’ activities that do not directly relate to their ability to decrease cholesterol. The proangiogenic and antiangiogenic characteristics of statins are among these pleiotropic effects. These angiogenic-modifying properties could offer new therapeutic applications. Statins stimulate or suppress angiogenesis in a biphasic manner. Whereas low doses of statin stimulate angiogenesis, high doses reduce protein prenylation and limit cell development and angiogenesis. In this review, we discuss how statins impact angiogenesis, with a particular focus on angiogenesis in stroke and cardiovascular disease (CVD).

AB - Inhibition of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase by statins is affected by inhibiting the active site of the enzyme in a competitive manner. Statins reduce plasma cholesterol by inhibiting its de novo synthesis. In addition, statins impart ‘pleiotropic’ activities that do not directly relate to their ability to decrease cholesterol. The proangiogenic and antiangiogenic characteristics of statins are among these pleiotropic effects. These angiogenic-modifying properties could offer new therapeutic applications. Statins stimulate or suppress angiogenesis in a biphasic manner. Whereas low doses of statin stimulate angiogenesis, high doses reduce protein prenylation and limit cell development and angiogenesis. In this review, we discuss how statins impact angiogenesis, with a particular focus on angiogenesis in stroke and cardiovascular disease (CVD).

KW - Angiogenesis

KW - Cardiovascular

KW - Ischemic heart disease

KW - Statins

KW - Vascularization

UR - http://www.scopus.com/inward/record.url?scp=85135508972&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2022.07.010

DO - 10.1016/j.drudis.2022.07.010

M3 - Article

C2 - 35872297

AN - SCOPUS:85135508972

SN - 1359-6446

VL - 27

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 10

M1 - 103325

ER -

Pleiotropic properties of statins via angiogenesis modulation in cardiovascular disease

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this